Teva Pharmaceutical and CureTech have announced the positive Phase II results for CT-011, an anti-PD-1 monoclonal antibody.

The three-month study included patients with diffuse large B-cell lymphoma (DLBCL) and showed that the drug increased the number of specific T-cells responsible for the maintenance of long-term immunologic memory.

The preliminary analysis also indicates that 70% of the patients treated with CT-011 were progression-free at the end of the follow-up period, as compared to only 47% in the historical control.

The final Phase II results for CT-011 are expected to be available during Q3 of 2011.

CT-011 blocks the PD-1 programmed death receptor and revitalises the body’s own immune system.

DLBCL is an aggressive type of non-Hodgkin’s Lymphoma (NHL) affecting about 40% of all NHL patients.